Single Site, Open-label, Randomized, Two Treatments, Two Periods, Two Sequences, Crossover Trial to Evaluate the Bioequivalence of Two Delayed-release Oral Formulations of a Fixed Combination of Doxylamine Succinate 10 mg/Pyridoxine Hydrochloride 10 mg (Test Product: Product of Tecnandina, S.A. TENSA; Reference Product: Diclegis (Registered Trademark) Product of Duchesnay Inc.) After a Single Administration of Two Tablets to Healthy Women Under Fasting Conditions
Latest Information Update: 04 Nov 2021
Price :
$35 *
At a glance
- Drugs Doxylamine/pyridoxine (Primary)
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors Grunenthal
- 18 Jun 2019 Planned initiation date changed from 1 May 2019 to 1 Jun 2019.
- 18 Jun 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 24 Apr 2019 New trial record